DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway

Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. To discover kinases that drive p...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research Vol. 25; no. 18; pp. 5608 - 5622
Main Authors: Kothari, Vishal, Goodwin, Jonathan F, Zhao, Shuang G, Drake, Justin M, Yin, Yi, Chang, S Laura, Evans, Joseph R, Wilder-Romans, Kari, Gabbara, Kristina, Dylgjeri, Emanuela, Chou, Jonathan, Sun, Grace, Tomlins, Scott A, Mehra, Rohit, Hege, Kristen, Filvaroff, Ellen H, Schaeffer, Edward M, Karnes, R Jeffrey, Quigley, David A, Rathkopf, Dana E, He, Housheng H, Speers, Corey, Spratt, Daniel E, Gilbert, Luke A, Ashworth, Alan, Chinnaiyan, Arul M, Raj, Ganesh V, Knudsen, Karen E, Feng, Felix Y
Format: Journal Article
Language:English
Published: United States 15-09-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression and . DNA-dependent protein kinase ( ) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of suppressed the growth of both -dependent and -independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with . We found that interacts with the Wnt transcription factor and is critical for -mediated transcription. Our data show that drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conception and design: J.F. Goodwin, J.R. Evans, S.A. Tomlins, K. Hege, E.M. Schaeffer, C. Speers, K.E. Knudsen, F.Y. Feng
Co-senior authors
Writing, review, and/or revision of the manuscript: V. Kothari, J.F. Goodwin, S.G. Zhao, Y. Yin, S.L. Chang, J.R. Evans, E. Dylgjeri, J. Chou, S.A. Tomlins, R. Mehra, K. Hege, E.H. Filvaroff, E.M. Schaeffer, R.J. Karnes, D.A. Quigley, D.E. Rathkopf, H.H. He, C. Speers, D.E. Spratt, L.A. Gilbert, A. Ashworth, A.M. Chinnaiyan, G.V. Raj, K.E. Knudsen, F.Y. Feng
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): V. Kothari, J.F. Goodwin, J.M. Drake, Y. Yin, K. Wilder-Romans, J. Chou, G. Sun, R.J. Karnes, D.E. Rathkopf, C. Speers, G.V. Raj, F.Y. Feng
Study supervision: V. Kothari, F.Y. Feng
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V. Kothari, S.G. Zhao, J.M. Drake, Y. Yin, S.L. Chang, J.R. Evans, E. Dylgjeri, J. Chou, E.H. Filvaroff, R.J. Karnes, D.A. Quigley, C. Speers, D.E. Spratt, A. Ashworth, G.V. Raj, K.E. Knudsen, F.Y. Feng
Development of methodology: V. Kothari, S.G. Zhao, Y. Yin, J.R. Evans, E. Dylgjeri, E.M. Schaeffer, F.Y. Feng
present address: Department of Urology, Northwestern University, Chicago, IL.
Author Contributions
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Kothari, K. Gabbara, D.E. Spratt
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-18-2387